Medicine Information

Advixa

Name: Advixa
Brand: Advixa
Rating: 4.5 (117 reviews)

Injection40 mgImmunosuppressant, TNF-alpha inhibitorATC: L04AB04

Generic Name

Adalimumab

Manufacturer

Hypothetical Biopharma Inc.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
advixa 40 mg injection	৳ 8,000.00	N/A

Description

Overview of the medicine

Advixa 40 mg Injection contains Adalimumab, a recombinant human monoclonal antibody that specifically binds to tumor necrosis factor alpha (TNFα). It is used to reduce inflammation and treat various autoimmune diseases.

Uses & Indications

Rheumatoid Arthritis (moderate to severe)

Psoriatic Arthritis

Ankylosing Spondylitis

Crohn's Disease (moderate to severe)

Ulcerative Colitis (moderate to severe)

Plaque Psoriasis (moderate to severe chronic)

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis (polyarticular)

Non-infectious Intermediate, Posterior, and Panuveitis

Dosage

Adults

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis: 40 mg every other week. Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa: Initial higher doses (e.g., 160 mg then 80 mg) followed by 40 mg every other week.

Elderly

No specific dose adjustment is required in elderly patients, but monitor closely for adverse events due to increased susceptibility.

Renal_impairment

No specific dose adjustment is required for patients with renal impairment.

How to Take

Administer by subcutaneous injection. The first dose should be administered under the supervision of a healthcare professional. Patients may be trained to self-inject.

Mechanism of Action

Adalimumab selectively binds to human TNFα, a naturally occurring cytokine involved in normal inflammatory and immune responses. It blocks the interaction of TNFα with its cell surface receptors (p55 and p75), thereby neutralizing the biological function of TNFα.

Pharmacokinetics

Onset

Clinical response typically observed within 2-4 weeks for most indications.

Excretion

Elimination primarily via catabolism of IgG; minimal renal excretion.

Half life

The mean terminal elimination half-life is approximately 10 to 20 days.

Absorption

Following subcutaneous administration, the mean absolute bioavailability is approximately 64%.

Metabolism

Adalimumab is catabolized in the same manner as endogenous IgG, not via CYP450 enzymes.

Side Effects

Contraindications

Active serious infections, including chronic or localized infections (e.g., sepsis, tuberculosis, opportunistic infections).
Moderate to severe heart failure (NYHA Class III/IV).
Hypersensitivity to adalimumab or any of the excipients.

Drug Interactions

Live Vaccines

Avoid concomitant administration of live vaccines.

Anakinra/Abatacept

Increased risk of serious infection; concomitant use not recommended.

Other Immunosuppressants (e.g., Methotrexate)

Concomitant use may increase efficacy but also the risk of infection. Use with caution.

Storage

Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light. Do not shake.

Overdose

No dose-limiting toxicity was observed during clinical trials. In case of an overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment initiated.

Pregnancy & Lactation

Use during pregnancy only if clearly needed and after careful assessment of risks and benefits. Small amounts may be present in breast milk; consider developmental and health benefits of breastfeeding along with the mother’s clinical need for Advixa.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

1 prefilled syringe/pen per pack

Shelf Life

Typically 24 months when stored as recommended.

Availability

Hospitals, Specialized Pharmacies

Approval Status

Approved (Biosimilar)

Patent Status

Biosimilar available (Original patent expired)

WHO Essential Medicine

Yes

Clinical Trials

Adalimumab has undergone extensive clinical trials supporting its efficacy and safety across multiple indications. Biosimilar versions like Advixa undergo studies to demonstrate similarity in efficacy, safety, and immunogenicity to the originator product.

Lab Monitoring

Complete Blood Count (CBC) with differential
Liver Function Tests (LFTs)
Renal function tests
Tuberculosis (TB) screening (prior to initiation and periodically during therapy)
Hepatitis B screening (prior to initiation)

Doctor Notes

Prior to initiation, screen patients for active or latent tuberculosis and hepatitis B infection.
Monitor patients closely for signs and symptoms of infection during and after treatment.
Educate patients on the importance of adhering to the treatment schedule and reporting adverse events promptly.
Advise against live vaccination concurrently.

Patient Guidelines

Follow proper injection technique as instructed by your healthcare provider.
Report any signs of infection (fever, persistent cough, unexplained weight loss) immediately.
Avoid live vaccines while on Advixa.
Attend all scheduled follow-up appointments and lab tests.

Missed Dose Advice

If a dose is missed, inject the next dose as soon as you remember. Then, take your next dose at your regularly scheduled time. Do not inject a double dose to make up for a missed one.

Driving Precautions

Advixa may cause dizziness or visual disturbances. If you experience these symptoms, avoid driving or operating machinery.

Lifestyle Advice

Maintain a healthy lifestyle, including a balanced diet and regular exercise, as advised by your doctor.
Avoid close contact with people who have active infections.